Chiesi USA Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
28
About the Report
About the Report
Summary
Chiesi USA Inc (Chiesi USA), a subsidiary of Chiesi Farmaceutici S.p.A, is a specialty pharmaceutical company. It researches, develops, produces and commercializes therapies in cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. The company's product portfolio comprises Cardene I.V. (nicardipine hydrochloride); Curosurf (poractant alfa); Zyflo (zileuton), Argatroban injection (Argatroban); Bethkis (tobramycin) and Retavase (reteplase). It offers products to retail pharmacy chains, wholesalers, group purchasing organizations, hospital systems and specialty pharmacies.Chiesi USA is headquartered in Cary, North Carolina, the US.
Chiesi USA Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chiesi USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 10
Licensing Agreements 12
Palladio Biosciences Enters into Agreement with Chiesi USA 12
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 13
Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 14
Asset Transactions 15
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 15
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 16
Acquisition 17
Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For USD 255 Million 17
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To USD 150 Million 19
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 21
Chiesi USA Inc-Key Competitors 22
Chiesi USA Inc-Key Employees 23
Chiesi USA Inc-Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
May 21, 2018: Triangle Business Journal Awards Chiesi USA, Inc. Second Consecutive Corporate Philanthropy Award 25
Government and Public Interest 26
May 03, 2018: NCBiotech Awards USD 2.65 Million in Grants, Loans in Two Latest Quarters 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28
List of Figure
List of Figures
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Chiesi USA Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chiesi USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chiesi USA Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Chiesi USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 10
Palladio Biosciences Enters into Agreement with Chiesi USA 12
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 13
Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 14
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 15
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 16
Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For USD 255 Million 17
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To USD 150 Million 19
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 21
Chiesi USA Inc, Key Competitors 22
Chiesi USA Inc, Key Employees 23
Chiesi USA Inc, Subsidiaries 24
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.